Pharma BD Deal Intelligence
Cubist Pharmaceuticals, Inc. / Calixa Therapeutics, Inc.
2009 · Acquisition/Merger · $402M · Complete
Announcement Sentiment
88
Strongly positive
$92.5M upfront cash + up to $310M milestones. CXA-101 (ceftolozane/tazobactam, Zerbaxa) anti-infective. Source: Fierce Biotech, Cubist 10-K.
Key facts
- Announced Dec 16, 2009
- Deal value $402M
- Deal type Acquisition/Merger
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals